Dr. Lin Shen’s Team Confirms Promising Efficacy of Immunotherapy Combined with Chemotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal

Dr. Lin Shen’s Team Confirms Promising Efficacy of Immunotherapy Combined with Chemotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal

2024.09.27
In April 2024, the 115th Annual Meeting of the American Association for Cancer Research (AACR) was held in San Diego, USA. As a global bellwether for new cancer drug development, the AACR meeting showcased numerous cutting-edge research findings in the field of oncology. One such study, conducted by Dr. Lin Shen's team from Peking Cancer Hospital, evaluated camrelizumab combined with chemotherapy as a neoadjuvant treatment for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC). This single-center, randomized, Phase II trial was selected for poster presentation at the conference, and Oncology Digest - Digestive Oncology News has summarized the key findings for readers.
Dr. Xiubao Ren: Exploring Tumor Immunotherapy from a “Reverse” Perspective – The Practice of Reverse Immune Editing Therapy

Dr. Xiubao Ren: Exploring Tumor Immunotherapy from a “Reverse” Perspective – The Practice of Reverse Immune Editing Therapy

2024.09.27
The 5th Tianjin International Lymphoma Conference was successfully held from September 6 to 8, 2024. The conference featured 12 specialized sessions, including immunotherapy, basic translational research, and new drug development, providing a platform for international academic exchange and collaboration. During the event, Hematology Frontier invited Dr. Xiubao Ren from Tianjin Medical University Cancer Institute and Hospital to share insights on the progress of clinical trials in reverse immune editing therapy and its future application prospects in cancer treatment.
Dr. Shuquan Cheng: Common Factors Hindering Functional Cure in Chronic Hepatitis B

Dr. Shuquan Cheng: Common Factors Hindering Functional Cure in Chronic Hepatitis B

2024.09.26
The reduction of hepatitis B surface antigen (HBsAg) levels in treated chronic hepatitis B (CHB) patients is closely linked to decreased risks of cirrhosis and even liver cancer. However, spontaneous HBsAg clearance occurs in less than 1% of patients per year. As CHB prevention and treatment guidelines continue to evolve both domestically and internationally, more patients are now pursuing "functional cures" through nucleos(t)ide analogs (NAs) combined with or followed by pegylated interferon (PEG-IFN) treatment. This approach offers the possibility of reducing or eliminating long-term or lifelong medication use. Clinically, even when patients use similar regimens aimed at achieving a functional cure, many continue to struggle along the difficult path to achieving HBsAg seroclearance, let alone reaching the ideal treatment endpoint of HBs seroconversion. Thus, understanding and recognizing the potential factors influencing functional cure is crucial for timely evaluation and intervention. This article summarizes the possible factors affecting CHB functional cure based on both domestic and international research to date.
Chinese Innovative Drug Takes the International Stage, Offering New Treatment Options for Intermediate and High-Risk Myelofibrosis Patients

Chinese Innovative Drug Takes the International Stage, Offering New Treatment Options for Intermediate and High-Risk Myelofibrosis Patients

2024.09.26
From September 13 to 17, 2024, the European Society for Medical Oncology (ESMO) Annual Meeting is being held in Barcelona, Spain. As one of the top international oncology conferences, the event gathers experts and scholars from around the world to share cutting-edge research and discuss future developments. In the Mini Oral Session on Hematologic Malignancies, Dr. Ling Pan from West China Hospital, Sichuan University, presented a pivotal phase II study comparing rovatirelinib with hydroxyurea for the treatment of intermediate and high-risk myelofibrosis (MF). The results demonstrated significant benefits in both efficacy and safety for rovatirelinib, offering a new potential treatment option for MF patients. Hematology Frontier invited Dr. Ling Pan to discuss the current landscape and challenges in the diagnosis and treatment of MF, provide insights into this pivotal study, and share her experiences at the ESMO conference.
BV Combined with R2 Regimen Significantly Improves Overall Survival in Patients with Relapsed/Refractory DLBCL

BV Combined with R2 Regimen Significantly Improves Overall Survival in Patients with Relapsed/Refractory DLBCL

2024.09.26
The treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has always been a significant challenge and a hot topic in the field of hematologic malignancies. For these patients, treatment options are extremely limited after multiple lines of therapy. Their salvage therapy has a low remission rate and short survival time. Currently, there is an urgent need for new effective treatment regimens to improve patient outcomes. The 12th Annual Meeting of the Society for Hematologic Oncology (SOHO 2024) was held in Houston, USA, from September 4th to 7th, 2024, bringing together top experts in the field of hematologic malignancies worldwide to exchange the latest research findings and discuss new therapeutic strategies. During the conference, Dr. Christopher A. Yasenchak from the Willamette Valley Cancer Institute and Rsearch Center was selected for an oral presentation titled 'Brentuximab Vedotin (BV) in Combination With Lenalidomide (Len) and Rituximab (R) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results From the Phase 3 ECHELON-3 Study' (Abstract Number: ABCL-711). Hematology Frontier specially invited Professor Christopher A. Yasenchak to interpret the efficacy and clinical significance of the BV+R2 (Brentuximab Vedotin combined with Rituximab and Lenalidomide) regimen in the ECHELON-3 study.
Peking Cancer Hospital Team’s PD-1/CTLA-4 Dual-Target Antibody Combined with Chemotherapy as First-Line Treatment for Advanced Gastric Cancer

Peking Cancer Hospital Team’s PD-1/CTLA-4 Dual-Target Antibody Combined with Chemotherapy as First-Line Treatment for Advanced Gastric Cancer

2024.09.26
Dr. Jiafu Ji, Dr. Ziyu Li, and Dr.  Lin Shen from Peking Cancer Hospital have co-authored a research paper titled “Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial”, published online in Nature Medicine. The study addresses several critical clinical issues, such as the limited benefit of PD-1 monoclonal antibody treatment, the high incidence of adverse effects with PD-1 and CTLA-4 combination therapy, and the ineffectiveness of PD-1 combined with chemotherapy in patients with low or negative CPS scores. To tackle these challenges, the researchers innovatively employed a domestically developed PD-1/CTLA-4 dual-target antibody in the COMPASSION-04 study, marking the first clinical trial globally to evaluate this combination as a first-line treatment for advanced gastric cancer.
Dr. Lin Shen: Focusing on Innovative Targets, Advancing Translational Research, and Promoting the Healthy Development of Digestive System Tumors

Dr. Lin Shen: Focusing on Innovative Targets, Advancing Translational Research, and Promoting the Healthy Development of Digestive System Tumors

2024.09.26
In June 2024, the 14th Annual Meeting of the Chinese Gastrointestinal Oncology Group (CGOG) and the Peking University Digestive Tumor Forum was held in Beijing. With the theme of "Innovation, Win-Win, Excellence," the conference focused on precision diagnosis and treatment, as well as translational research in digestive system tumors. It also covered the latest research progress and challenges in clinical practice. During the event, a reporter from Oncology Frontier conducted an exclusive interview with the conference chair, Dr. Lin Shen from Peking Cancer Hospital. Below is the interview for readers.
SOHO 2024 | Dr. Eunice Wang Discusses the Latest Advances in Menin Inhibitor Research

SOHO 2024 | Dr. Eunice Wang Discusses the Latest Advances in Menin Inhibitor Research

2024.09.25
The 12th Annual Meeting of the Society for Hematologic Oncology (SOHO 2024) took place in Houston, USA, from September 4th to 7th, 2024, gathering top experts in the field of hematologic malignancies from around the world to exchange the latest research findings and discuss new therapeutic strategies. At the conference, Dr. Eunice Wang from the Roswell Park Comprehensive Cancer Center in the United States presented the latest developments in the research and development of Menin inhibitors. For this, 'Oncology Frontier - Hematology Frontier' specially interviewed Dr. Eunice Wang and provided a wonderful interpretation around this topic.
Dr. Feng Shen: Climb to the peak! The ASAP model continues to break through the depth and breadth of screening for Chinese liver cancer risk groups

Dr. Feng Shen: Climb to the peak! The ASAP model continues to break through the depth and breadth of screening for Chinese liver cancer risk groups

2024.09.25
China is a major country with liver cancer, and the incidence rate and mortality rate of liver cancer account for about half of the world's total. Early identification of high-risk populations and early diagnosis of liver cancer are key to improving the overall survival rate of patients. Since the discovery of vitamin K in 1929, researchers have gradually confirmed the important role of serum abnormal prothrombin caused by its deficiency in the diagnosis of liver cancer. In 2019, Dr. Feng Shen and his team from Eastern Hepatobiliary Surgery Hospital, the third affiliated hospital of the Naval Medical University, collaborated with other top hospital teams in China to establish and validate the ASAP risk prediction model. Since then, the ASAP model has continuously broken through the prediction limitations of hepatitis B-related liver cancer, and has achieved frequent success in predicting hepatitis C-related liver cancer, non-alcoholic fatty liver disease-related liver cancer, and early recurrence diagnosis of liver cancer.